Literature DB >> 19259281

Second- and third-line treatment options for unresectable metastatic colorectal cancer.

Leonard B Saltz1.   

Abstract

Entities:  

Year:  2008        PMID： 19259281      PMCID： PMC2632568     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  3 in total

1.  A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

Authors:  J Tol; M Koopman; C J Rodenburg; A Cats; G J Creemers; J G Schrama; F L G Erdkamp; A H Vos; L Mol; N F Antonini; C J A Punt
Journal:  Ann Oncol       Date:  2008-02-13       Impact factor: 32.976

2.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

3.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

Authors:  Bert H O'Neil; Robert Allen; David R Spigel; Thomas E Stinchcombe; Dominic T Moore; Jordan D Berlin; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544
  3 in total
  1 in total

1.  Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial.

Authors:  Andor F van den Hoven; Jip F Prince; Rutger C G Bruijnen; Helena M Verkooijen; Gerard C Krijger; Marnix G E H Lam; Maurice A A J van den Bosch
Journal:  Trials       Date:  2016-10-25       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.